EDITION 2.7 MONOGRAPH [8.1] • ID: TIP-MED-000129

Amoxicillin Trihydrate

Aminopenicillin Beta-Lactam Antibiotic (Bactericidal Cell-Wall Peptidoglycan Synthesis Inhibitor; WHO 'Access' Group) • Schedule H (Drugs Rules, 1945 — Prescription Only)

⚖️ Compare with Another Medicine

Level 1 — Quick Professional Summary (At a Glance)

1. Generic Name & Identifier:
Amoxicillin Trihydrate
Monograph Code: [8.1] | Stable ID: TIP-MED-000129

2. Verified Indian Market Brands:
Mox (Sun Pharma), Novamox (Cipla), Almox (Alkem)

3. Pharmacological & Therapeutic Class:
Aminopenicillin Beta-Lactam Antibiotic (Bactericidal Cell-Wall Peptidoglycan Synthesis Inhibitor; WHO 'Access' Group)
Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08)

4. Dosage Forms, Strengths & Route:
Oral Capsules / Dispersible Tablets: 250 mg, 500 mg; Paediatric Dry Syrup for Reconstitution: 125 mg/5 mL, 250 mg/5 mL; Drops: 100 mg/mL
Route: Oral / Parenteral / Topical as specified by formulation

9–10. Mechanism of Action & Pharmacodynamics

Bactericidal time-dependent beta-lactam antibiotic (`fT > MIC`) that binds to bacterial Penicillin-Binding Proteins (PBPs 1A, 2, 3), inhibiting transpeptidation of peptidoglycan cell-wall cross-links and triggering autolysin-mediated bacterial cell lysis.

12. Therapeutic Indications

Community-acquired respiratory tract infections (acute otitis media, bacterial pharyngotonsillitis, sinusitis, community-acquired pneumonia)
Helicobacter pylori eradication regimens (in combination with Clarithromycin/Metronidazole and a PPI) and dental abscesses

13 & 16. Contraindications, Precautions & Warnings

🚫 Contraindications:

History of immediate IgE-mediated hypersensitivity (anaphylaxis, angioedema, bronchospasm, Stevens-Johnson syndrome) to Penicillins or any Beta-Lactam antibiotic
Avoid in suspected infectious mononucleosis (Epstein-Barr virus) due to >70% incidence of generalised maculopapular morbilliform rash

⚠️ Precautions & Warnings:

No routine hepatic dose adjustment required for plain Amoxicillin (monitor LFTs if co-formulated with Clavulanate, which carries cholestatic jaundice risk).

14. Dosage & Administration Context (Educational Reference Summary)

Dosing & Indication Context: Educational Reference Summary: Standard adult oral regimen is 250 mg to 500 mg every 8 hours (TID) or 875 mg every 12 hours (BID) for 5–7 days depending on infection site and severity (H. pylori: 1000 mg BID).
Administration & Timing: May be taken with or without food (taking at the start of a light meal improves GI tolerability, particularly when combined with Clavulanic Acid). Space doses evenly every 8 hours (`fT > MIC` time-dependent killing).

Level 2 — Detailed Pharmacology, PK, Interactions & Special Populations

11 & 19. Pharmacokinetics (ADME), Renal & Hepatic Considerations

Pharmacokinetic Profile: Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.

Renal Considerations: Excreted primarily unchanged via glomerular filtration and tubular secretion: CrCl 10–30 mL/min: 250–500 mg every 12 hours; CrCl < 10 mL/min: 250–500 mg every 24 hours; administer dose after haemodialysis session.

Hepatic Considerations: No routine hepatic dose adjustment required for plain Amoxicillin (monitor LFTs if co-formulated with Clavulanate, which carries cholestatic jaundice risk).

15 & 17. Adverse Effects & Clinically Significant Drug Interactions

Adverse Effects:

Hypersensitivity reactions ranging from delayed maculopapular rash to immediate IgE-mediated urticaria and anaphylaxis
Diarrhoea, nausea, candidal superinfection (oral/vulvovaginal thrush), rare Clostridioides difficile colitis

Major Drug Interactions:

Methotrexate: Penicillins compete for renal organic anion tubular secretion (OAT1/OAT3), reducing Methotrexate clearance and risking severe myelosuppression.
Allopurinol: Co-administration significantly increases the incidence of non-allergic maculopapular skin rash.
Warfarin / Oral Anticoagulants: Alteration of gut flora may potentiate INR elevation; monitor INR during systemic antibiotic therapy.

18, 20, 21 & 22. Special Populations, Monitoring, Counselling & Storage

Pregnancy, Lactation, Paediatric & Geriatric Use: Evaluate maternal-foetal benefit-risk ratio and age-appropriate organ function before prescribing.

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Patient Counselling Points:

Always confirm absence of Penicillin allergy before dispensing the first dose.
Complete the full prescribed antibiotic course at evenly spaced intervals (every 8 hours for TID) even if fever subsides after 48 hours.
For paediatric dry syrup powder: reconstitute to the ring mark with boiled and cooled water, shake well before each dose, and discard unused suspension after 7–10 days (per manufacturer label).

Storage & Dispensing Governance: Store capsules below 25°C in a dry place; reconstituted oral suspensions should be stored in a cool place / refrigerator (2°C–8°C) and discarded after 7–14 days.

Visual Pharmacology Mechanism Diagram (PLATE-8.9)

Figure 8.9: Mechanisms of action of major antibacterial classes across bacterial cell-wall synthesis, 30S/50S ribosomal protein translation, nucleic acid replication, and folic acid biosynthesis.

23. Traceable Source References & Jurisdiction

Primary Reference Record: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) by THE INDIAN PHARMACIST Editorial Reference; ICMR Antimicrobial Treatment Guidelines; NFI 7th Ed (2026).

Authoritative Verification Portals: Indian Pharmacopoeia Commission (IPC) • CDSCO (India Jurisdiction) • NCBI Bookshelf • DailyMed (US FDA Label Reference)

Last Checked Date: 2026-11-08 • Related Study Guide: Antimicrobial Stewardship & PK/PD Optimization →

← Back to 519-Record Medicine Reference 📖 Read Related Clinical Guide → ⚠️ Report Error / Suggest Correction